True, but until then... it is trading below the cash on hand now. I got a hundred other biopharma companies for you that are in far more precarious conditions than this if you really want to stick to that argument.
"The Company committed to make an initial capital contribution of up to $36.3 million in fiscal 2012 and, additional capital contributions of up to an additional $36.3 million beginning after December 31, 2012, primarily to fund the construction of the Solazyme Bunge JV Plant. The Company and Bunge each contributed capital in the amount of $59.3 million through September 30, 2014, comprised of $37.0 million , $12.3 million and $10.0 million during the nine months ended September 30, 2014 and during the years ended December 31, 2013 and 2012, respectively, to the Solazyme Bunge JV. In August 2014, the Company contributed $6.5 million to the Solazyme Bunge JV through a reduction in the Company’s receivables due from the Solazyme Bunge JV of $6.5 million . The Company and Bunge each contributed capital in the amount of $1.0 million in October 2014."
People make way too many assumptions. The board of directors comes up with this compensation schedule and it's based on a comparison of nearly 20 comparable companies in San Francisco. Hate the game and hate the players buts it's far from being unfair on an apples to apples comparison as to what is expected for the industry.
Solar + Enzyme; Misnomer now, but it's actually a good reminder of how they've been able to adapt to changing situations. Leave it the market to forget that time and time again.
Ftk is a great company and one that actually highlights why szym is in the right market when it comes to green solutions in the oilfields. Thanks for your two cents as you walk on by but encapso is quite differentiated from what you're referring to. Let me know when you find another targeted drilling lubricant additive rather than a frac solvent.
Not true as we're not anywhere close to peak demand for the product, and especially not true for a unique cost-saving solution during an environment of pricing pressure for drillers.
Encapso is also useful for vertical wells too, so let's not discount their recent trials in the middle east either. Someone has their eyes on that region when it comes to encapso as well
This is just an option exercise. He also didn't sell right away which is typical for many options exercises. Something worth mentioning considering the sales have stopped around the mid-$7 level again.
It's no insider buy as hes likely restricted from that for now, but it is another sign of confidence to exercise those options when the market's running away.